Preventive role of Indian black pepper in animal models of Alzheimer’s disease

Journal of Clinical and Diagnostic Research

Volumn 9, Issue 4, 2015, Pages FF01-FF04

  Subedee, Lokraj ^a   Suresh, R N ^a   Jayanthi, M K ^a   Kalabharathi, H L ^a   Satish, A M ^a   Pushpa, V H ^a  

^a JSS MEDICAL COLLEGE   (India)

Author keywords

Amyloid plaque; Cholinesterase; Dementia; Morris water maze; Piper nigrum

Indexed keywords

BLACK PEPPER EXTRACT; CHOLINESTERASE;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR; BIOCHEMISTRY; BLACK PEPPER; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG SYNTHESIS; HISTOPATHOLOGY; LATENT PERIOD; LEARNING; MALE; MEMORY; MORRIS WATER MAZE TEST; NONHUMAN; RAT;

ANIMALIA; PIPER NIGRUM; RATTUS;

EID: 84926321647     PISSN: 2249782X     EISSN: 0973709X     Source Type: Journal    
DOI: 10.7860/JCDR/2015/8953.5767     Document Type: Article

References (26)

1. Zhu D, et al. Central angiotensin II stimulation promotes β amyloid production in Sprague Dawley rats. Plos one. 2011;6(1):1-9.
2. Iqbal K, I Grundke-Iqbal. Alzheimer’s disease, a multifactorial disorder seeking multitherapies. Alzheimer’s & Dementia. 2010;6:420-24.
3. Small SA, Mayeux R. Alzheimer’s disease and related dementias. In: Rowland LP (Ed) Merritt’s Neurology, Lippincott Williams & Wilkins, Philadelphia, USA, 107-2005. pp. 771-776.
4. Dorman HJ, Deans SG. Antimicrobial agents from plants:antibacterial activity of plant volatile oils. J Appl Microbiol. 2000;(88):308-16.
5. HR El, Idaomar M, Alonso-Moraga A, Muñoz SA. Antimutagenic properties of bell and black pepper. Food Chem Toxicol.2003;41(1):41-47.
6. Vijayakumar RS, Surya D, Nalini N. Antioxidant efficiency of black pepper and piperine in rats with high fat diet induced oxidativestress. Redox Rep. 2004;9(2):105-10.
7. Salloway S, Ferris S, Kluger A, Goldman R, Griesing T, Kumar D, et al. Efficacy of donepezil in mild cognitive impairment: A randomized placebo-controlled trial. Neurology. 2004;63:651-57.
8. Courtney C, Farrell D, Gray R, Hills R, Lynch L, Sellwood E, et al. Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): Randomized double-blind trial. Lancet. 2004;363:2105-15.
9. Mantle D, Pickering AT, Perry E. Medical Plant extracts for treatment of dementia: A review of their pharmacology, efficacy and tolerability. CNS Drugs. 2000;13:201-13.
10. [www.alz.org/facts_figure-Alzheimer’sdiseasefactandfigure page 16].
11. Guide for the Care and Use of Laboratory Animals. NIH Publication No. 85-23. Available from: http://grants.nih.gov/grants/olaw/references/laba94.htm. [last revised on 1985].
12. Pappas BA, De La Torre JC, Davidson CM, Keyes MT, Fortin T. Chronic reduction of cerebral blood flow in the adult rat: Late emerging CA1 cell loss and memory dysfunction. Brain Res. 1996;708:50-58.
13. Tsakiris, KH schulpis, K marinou, P behrakis. Protective effect of L-cysteine and glutathione on the modulated suckling rat brain Na+-K+ ATPase and Mg ATPase activity induced by the invitro galactosemia. Pharmacological research. 2004;49:475-79.
14. Ono K, et al. Anti-amyloidogenic effects of antioxidants: Implications for the prevention and therapeutics of Alzheimer’s disease. Biochimica et Biophysica Acta. 2006;1762:575-86.
15. Bartus RT. On neurodegenerative disease, models and treatment strategies: lessons learned and lessons forgotten, a generation following the cholinergic hypothesis. Experimental Neurology. 2000;0163:495-529.
16. Terry AV, Buccafusco JJ. The cholinergic hypothesis of age and Alzheimer’s disease-related cognitive deficits: recent challenges and their implications for novel drug development. The Journal of Pharmacology and Experimental Therapeutics. 2003;306:821-27.
17. Heinrich M, Teoh HL. Galanthamine from snowdrop - the development of a modern drug against Alzheimer’s disease from local Caucasian knowledge. Journal of Ethnopharmacology. 2004;92:147-62.
18. Eagger SA, Levy R, Sahakian BJ. Tacrine in Alzheimer’s disease. Lancet. 1991;337:989-92. Back to cited text no. 58.
19. Davis KL, Mohs RC, Davis BM, Levy MI, Horvath TB, Rosenberg GS, et al. Cholinergic treatment in Alzheimer’s disease: Implications for future research. In: Corkin S, Davis KL, Crowdon JH, Usdin E, Wurtman RJ, editors. Alzheimer’s disease: A report of progress in research. New York: Raven Press; 1982. pp. 483-94.
20. Rösler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-bianco P, et al. Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomized controlled trial. British Medical Journal. 1999;318:633-40.
21. Brenner GM Pharmacology. WB Saunders Company, Philadelphia (2000).
22. Rahman AU, Choudhary MI Bioactive natural products as a potential source of new pharmacophores, a theory of memory. Pure and Applied Chemistry. 2001;73:555-60.
23. Elufioye TO, Obuotor EM, Sennuga AT, Agbedahunsi JM, Adesanya SA. Acetylcholinesterase and butyrylcholinesterase inhibitory activity of some selected Nigerian medicinal plants. Brazilian Journal of Pharmacognosy. 2010;20:472-77.
24. Roberson MR, Harrell LE. Cholinergic activity and amyloid precursor protein metabolism. Brain Res Brain Res Rev. 1997;25:50-69.
25. Halliwell B, Gutteridge JMC. Oxygen radicals in the nervous system. Trends in Neurosciences. 1985;8:22-26.
26. Floyd RA, Hensley K. Oxidative stress in brain aging. Implications for therapeutics of neurodegenerative diseases. Neurobiology of Aging. 2002;23:795-807.